Precigen (NASDAQ:PGEN) Stock Price Down 5.5% – Should You Sell?

Precigen, Inc. (NASDAQ:PGEN) shares were down 5.5% during mid-day trading on Friday . The company traded as low as $6.09 and last traded at $6.1350. Approximately 4,476,032 shares traded hands during trading, a decline of 3% from the average daily volume of 4,618,531 shares. The stock had previously closed at $6.49.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of Precigen from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. HC Wainwright boosted their target price on Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Citizens Jmp upped their target price on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Precigen Stock Down 5.2%

The company has a market capitalization of $2.19 billion, a PE ratio of -5.92 and a beta of 1.02. The stock’s fifty day moving average is $5.46 and its two-hundred day moving average is $4.56. The company has a current ratio of 4.58, a quick ratio of 3.89 and a debt-to-equity ratio of 2.15.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. The business had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The business’s revenue for the quarter was up 6322.7% compared to the same quarter last year. As a group, analysts predict that Precigen, Inc. will post 0.25 EPS for the current year.

Insider Activity at Precigen

In other news, CEO Helen Sabzevari sold 346,836 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the sale, the chief executive officer owned 3,768,872 shares in the company, valued at $22,198,656.08. This trade represents a 8.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 42,924 shares of Precigen stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.85, for a total transaction of $251,105.40. Following the completion of the sale, the chief operating officer directly owned 497,751 shares in the company, valued at $2,911,843.35. This trade represents a 7.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 989,239 shares of company stock valued at $5,472,960 over the last quarter. 41.40% of the stock is currently owned by insiders.

Institutional Trading of Precigen

Hedge funds have recently made changes to their positions in the company. Xponance LLC lifted its position in shares of Precigen by 21.3% during the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 2,993 shares during the last quarter. Composition Wealth LLC increased its holdings in Precigen by 16.5% in the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 3,000 shares during the last quarter. Intech Investment Management LLC raised its stake in Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 3,137 shares during the period. Finally, Cetera Investment Advisers raised its stake in Precigen by 0.9% in the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock valued at $1,449,000 after acquiring an additional 3,250 shares during the period. 33.51% of the stock is currently owned by institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.